Advanced Young-Onset Adenoma Increases Colorectal Cancer Risk
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
MONDAY, Sept. 18, 2023 -- Advanced young-onset adenoma (YOA) increases the risk for new colorectal cancer (CRC) eightfold, according to a study published online in the September issue of the American Journal of Gastroenterology.
Yas Casey, M.D., from the VA Loma Linda Healthcare System in California, and colleagues compared the risk for incident and fatal CRC in adults aged younger than 50 years with YOA diagnosis versus those with a normal colonoscopy. The analysis included 54,284 U.S. veterans (aged 18 to 49 years) who received a colonoscopy between 2005 and 2016.
The researchers found that cumulative 10-year CRC incidence was 0.11 percent after any adenoma diagnosis, 0.18 percent after advanced YOA diagnosis, 0.10 percent after nonadvanced adenoma diagnosis, and 0.06 percent after normal colonoscopy. Incident CRC risk was eightfold higher in veterans with advanced adenoma versus those with normal colonoscopy (hazard ratio, 8.0). No differences in fatal CRC risk were seen across groups.
"Cumulative CRC incidence and mortality at 10 years among individuals with either young onset nonadvanced or advanced adenoma diagnosis were both relatively low," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Vaginal Cancer Incidence Increasing Globally
WEDNESDAY, July 3, 2024 -- The incidence of vaginal cancer is increasing globally, according to a study published online June 25 in BJOG: An International Journal of Obstetrics...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.